Recent studies, however, have indicated that in patients with NSCLC, anti‐PD‐L1 based therapies are mostly effective in tumors with high tumor associated expression of PD‐L1, where median overall survival is shown to increase significantly compared with standard of care platinum‐based chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.